Advertisement

Vaccines Against Escherichia coli

  • Barbara Nesta
  • Mariagrazia PizzaEmail author
Chapter
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 416)

Abstract

Escherichia coli has a complex and versatile nature and continuously evolves from non-virulent isolates to highly pathogenic strains causing severe diseases and outbreaks. Broadly protective vaccines against pathogenic E. coli are not available and the rising in both, multi-drug resistant and hypervirulent isolates, raise concern for healthcare and require continuous efforts in epidemiologic surveillance and disease monitoring. The evolving knowledge on E. coli pathogenesis mechanisms and on the mediated immune response following infection or vaccination, together with advances in the “omics” technologies, is opening new perspectives toward the design and development of effective and innovative E. coli vaccines.

References

  1. Ahmed B, Loos M, Vanrompay D, Cox E (2013a) Mucosal priming of the murine immune system against enterohemorrhagic Escherichia coli O157:H7 using Lactococcus lactis expressing the type III secretion system protein EspB. Vet Immunol Immunopathol 152(1–2):141–145PubMedGoogle Scholar
  2. Ahmed S, Byrd W, Kumar S, Boedeker EC (2013b) A directed intimin insertion mutant of a rabbit enteropathogenic Escherichia coli (REPEC) is attenuated, immunogenic and elicits serogroup specific protection. Vet Immunol Immunopathol 152(1–2):146–155PubMedGoogle Scholar
  3. Ahmed T, Bhuiyan TR, Zaman K, Sinclair D, Qadri F (2013c) Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea. Cochrane Database Syst Rev (7):CD009029Google Scholar
  4. Alerasol M, Mousavi Gargari SL, Nazarian S, Bagheri S (2014) Immunogenicity of a fusion protein comprising coli surface antigen 3 and labile B subunit of enterotoxigenic Escherichia coli. Iran Biomed J 18(4):212–218PubMedPubMedCentralGoogle Scholar
  5. Alteri CJ, Hagan EC, Sivick KE, Smith SN, Mobley HL (2009) Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog 5(9):e1000586PubMedPubMedCentralGoogle Scholar
  6. Amos GC, Hawkey PM, Gaze WH, Wellington EM (2014) Waste water effluent contributes to the dissemination of CTX-M-15 in the natural environment. J Antimicrob Chemother 69(7):1785–1791PubMedPubMedCentralGoogle Scholar
  7. Asadi Karam MR, Rezaei AA, Siadat SD, Habibi M, Bouzari S (2017) Evaluation of prevalence, homology and immunogenicity of dispersin among enteroaggregative Escherichia coli isolates from Iran. Iran Biomed J 21(1):40–47PubMedGoogle Scholar
  8. Asper DJ, Karmali MA, Townsend H, Rogan D, Potter AA (2011) Serological response of Shiga toxin-producing Escherichia coli type III secreted proteins in sera from vaccinated rabbits, naturally infected cattle, and humans. Clin Vaccine Immunol 18(7):1052–1057PubMedPubMedCentralGoogle Scholar
  9. Baldi DL, Higginson EE, Hocking DM, Praszkier J, Cavaliere R, James CE, Bennett-Wood V, Azzopardi KI, Turnbull L, Lithgow T, Robins-Browne RM, Whitchurch CB, Tauschek M (2012) The type II secretion system and its ubiquitous lipoprotein substrate, SslE, are required for biofilm formation and virulence of enteropathogenic Escherichia coli. Infect Immun 80(6):2042–2052PubMedPubMedCentralGoogle Scholar
  10. Barry EM, Wang J, Wu T, Davis T, Levine MM (2006) Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine 24(18):3727–3734PubMedGoogle Scholar
  11. Basu S (2015) Neonatal sepsis: the gut connection. Eur J Clin Microbiol Infect Dis 34(2):215–222PubMedGoogle Scholar
  12. Bauer HW, Alloussi S, Egger G, Blumlein HM, Cozma G, Schulman CC, Multicenter UTISG (2005) A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol 47(4):542–548 (discussion 548)PubMedGoogle Scholar
  13. Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS (2002) Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents 19(6):451–456PubMedGoogle Scholar
  14. Behrens RH, Cramer JP, Jelinek T, Shaw H, von Sonnenburg F, Wilbraham D, Weinke T, Bell DJ, Asturias E, Pauwells HL, Maxwell R, Paredes-Paredes M, Glenn GM, Dewasthaly S, Stablein DM, Jiang ZD, DuPont HL (2014) Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. Lancet Infect Dis 14(3):197–204PubMedGoogle Scholar
  15. Blaak H, Hamidjaja RA, van Hoek AH, de Heer L, de Roda Husman AM, Schets FM (2014) Detection of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli on flies at poultry farms. Appl Environ Microbiol 80(1):239–246PubMedPubMedCentralGoogle Scholar
  16. Brumbaugh AR, Mobley HL (2012) Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines 11(6):663–676PubMedPubMedCentralGoogle Scholar
  17. Brzuszkiewicz E, Gottschalk G, Ron E, Hacker J, Dobrindt U (2009) Adaptation of pathogenic E. coli to various niches: genome flexibility is the key. Genome Dyn 6:110–125PubMedGoogle Scholar
  18. Brzuszkiewicz E, Thurmer A, Schuldes J, Leimbach A, Liesegang H, Meyer FD, Boelter J, Petersen H, Gottschalk G, Daniel R (2011) Genome sequence analyses of two isolates from the recent Escherichia coli outbreak in Germany reveal the emergence of a new pathotype: Entero-aggregative-haemorrhagic Escherichia coli (EAHEC). Arch Microbiol 193(12):883–891PubMedPubMedCentralGoogle Scholar
  19. Cai K, Gao X, Li T, Wang Q, Hou X, Tu W, Xiao L, Tian M, Liu Y, Wang H (2011) Enhanced immunogenicity of a novel Stx2Am-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 29(5):946–952PubMedGoogle Scholar
  20. Carl MA, Ndao IM, Springman AC, Manning SD, Johnson JR, Johnston BD, Burnham CA, Weinstock ES, Weinstock GM, Wylie TN, Mitreva M, Abubucker S, Zhou Y, Stevens HJ, Hall-Moore C, Julian S, Shaikh N, Warner BB, Tarr PI (2014) Sepsis from the gut: the enteric habitat of bacteria that cause late-onset neonatal bloodstream infections. Clin Infect Dis 58(9):1211–1218PubMedPubMedCentralGoogle Scholar
  21. Chakraborty S, Harro C, DeNearing B, Ram M, Feller A, Cage A, Bauers N, Bourgeois AL, Walker R, Sack DA (2015) Characterization of mucosal immune responses to enterotoxigenic Escherichia coli vaccine antigens in a human challenge model: response profiles after primary infection and homologous rechallenge with strain H10407. Clin Vaccine Immunol 23(1):55–64PubMedGoogle Scholar
  22. Chen Q, Savarino SJ, Venkatesan MM (2006) Subtractive hybridization and optical mapping of the enterotoxigenic Escherichia coli H10407 chromosome: isolation of unique sequences and demonstration of significant similarity to the chromosome of E. coli K-12. Microbiology 152(Pt 4):1041–1054PubMedGoogle Scholar
  23. Chui H, Chan M, Hernandez D, Chong P, McCorrister S, Robinson A, Walker M, Peterson LA, Ratnam S, Haldane DJ, Bekal S, Wylie J, Chui L, Westmacott G, Xu B, Drebot M, Nadon C, Knox JD, Wang G, Cheng K (2015) Rapid, sensitive, and specific Escherichia coli H antigen typing by matrix-assisted laser desorption ionization-time of flight-based peptide mass fingerprinting. J Clin Microbiol 53(8):2480–2485PubMedPubMedCentralGoogle Scholar
  24. Cohen D, Orr N, Haim M, Ashkenazi S, Robin G, Green MS, Ephros M, Sela T, Slepon R, Ashkenazi I, Taylor DN, Svennerholm AM, Eldad A, Shemer J (2000) Safety and immunogenicity of two different lots of the oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Israeli young adults. Infect Immun 68(8):4492–4497PubMedPubMedCentralGoogle Scholar
  25. Cross AS (1994) Antiendotoxin antibodies: a dead end? Ann Intern Med 121(1):58–60PubMedGoogle Scholar
  26. Cross A, Artenstein A, Que J, Fredeking T, Furer E, Sadoff JC, Cryz SJ Jr (1994) Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. J Infect Dis 170(4):834–840PubMedGoogle Scholar
  27. Cryz SJ Jr, Cross AS, Sadoff JC, Wegmann A, Que JU, Furer E (1991) Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans. J Infect Dis 163(5):1040–1045PubMedGoogle Scholar
  28. Czerkinsky C, Holmgren J (2010) Topical immunization strategies. Mucosal Immunol 3(6):545–555PubMedGoogle Scholar
  29. Darsley MJ, Chakraborty S, DeNearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker R, Harro CD (2012) The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. Clin Vaccine Immunol 19(12):1921–1931PubMedPubMedCentralGoogle Scholar
  30. Das JK, Tripathi A, Ali A, Hassan A, Dojosoeandy C, Bhutta ZA (2013) Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus. BMC Publ Health 13(Suppl 3):S11Google Scholar
  31. Donnenberg MS, Finlay BB (2013) Combating enteropathogenic Escherichia coli (EPEC) infections: the way forward. Trends Microbiol 21(7):317–319PubMedPubMedCentralGoogle Scholar
  32. Dubreuil JD, Isaacson RE, Schifferli DM (2016) Animal enterotoxigenic Escherichia coli. EcoSal Plus 7(1)Google Scholar
  33. Durant L, Metais A, Soulama-Mouze C, Genevard JM, Nassif X, Escaich S (2007) Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infect Immun 75(4):1916–1925PubMedGoogle Scholar
  34. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA (2005) Diversity of the human intestinal microbial flora. Science 308(5728):1635–1638PubMedPubMedCentralGoogle Scholar
  35. Frank C, Faber MS, Askar M, Bernard H, Fruth A, Gilsdorf A, Hohle M, Karch H, Krause G, Prager R, Spode A, Stark K, Werber D, H. U. S. i. team (2011) Large and ongoing outbreak of haemolytic uraemic syndrome, Germany, May 2011. Euro Surveill 16(21)Google Scholar
  36. Franz E, Veenman C, van Hoek AH, de Roda Husman A, Blaak H (2015) Pathogenic Escherichia coli producing Extended-Spectrum beta-Lactamases isolated from surface water and wastewater. Sci Rep 5:14372PubMedPubMedCentralGoogle Scholar
  37. Fratamico PM, DebRoy C, Liu Y, Needleman DS, Baranzoni GM, Feng P (2016) Advances in molecular serotyping and subtyping of Escherichia coli. Front Microbiol 7:644PubMedPubMedCentralGoogle Scholar
  38. Frey C, Obolensky W, Wyss H (1986) Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier. Urol Int 41(6):444–446PubMedGoogle Scholar
  39. Gao X, Cai K, Shi J, Liu H, Hou X, Tu W, Xiao L, Wang Q, Wang H (2009) Immunogenicity of a novel Stx2B-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 27(14):2070–2076PubMedGoogle Scholar
  40. Gensollen T, Iyer SS, Kasper DL, Blumberg RS (2016) How colonization by microbiota in early life shapes the immune system. Science 352(6285):539–544PubMedPubMedCentralGoogle Scholar
  41. Geue L, Monecke S, Engelmann I, Braun S, Slickers P, Ehricht R (2014) Rapid microarray-based DNA genoserotyping of Escherichia coli. Microbiol Immunol 58(2):77–86PubMedGoogle Scholar
  42. Giddings SL, Stevens AM, Leung DT (2016) Traveler’s diarrhea. Med Clin North Am 100(2):317–330PubMedPubMedCentralGoogle Scholar
  43. Giuliani MM, Del Giudice G, Giannelli V, Dougan G, Douce G, Rappuoli R, Pizza M (1998) Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 187(7):1123–1132PubMedPubMedCentralGoogle Scholar
  44. Gohar A, Abdeltawab NF, Fahmy A, Amin MA (2016) Development of safe, effective and immunogenic vaccine candidate for diarrheagenic Escherichia coli main pathotypes in a mouse model. BMC Res Notes 9:80PubMedPubMedCentralGoogle Scholar
  45. Gould LH, Mody RK, Ong KL, Clogher P, Cronquist AB, Garman KN, Lathrop S, Medus C, Spina NL, Webb TH, White PL, Wymore K, Gierke RE, Mahon BE, Griffin PM, G. Emerging Infections Program Foodnet Working (2013) Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000–2010: epidemiologic features and comparison with E. coli O157 infections. Foodborne Pathog Dis 10(5):453–460Google Scholar
  46. Habibi M, Asadi Karam MR, Bouzari S (2016) Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis. APMIS 124(6):444–452PubMedGoogle Scholar
  47. Hays MP, Ericsson AC, Yang Y, Hardwidge PR (2016) Vaccinating with conserved Escherichia coli antigens does not alter the mouse intestinal microbiome. BMC Res Notes 9(1):401PubMedPubMedCentralGoogle Scholar
  48. He Y, Xiang Z, Mobley HL (2010) Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development. J Biomed Biotechnol 2010:297505PubMedPubMedCentralGoogle Scholar
  49. Hernandes RT, De la Cruz MA, Yamamoto D, Giron JA, Gomes TA (2013) Dissection of the role of pili and type 2 and 3 secretion systems in adherence and biofilm formation of an atypical enteropathogenic Escherichia coli strain. Infect Immun 81(10):3793–3802PubMedPubMedCentralGoogle Scholar
  50. Hidas G, Billimek J, Nam A, Soltani T, Kelly MS, Selby B, Dorgalli C, Wehbi E, McAleer I, McLorie G, Greenfield S, Kaplan SH, Khoury AE (2015) Predicting the risk of breakthrough urinary tract infections: primary vesicoureteral reflux. J Urol 194(5):1396–1401PubMedGoogle Scholar
  51. Honish L, Punja N, Nunn S, Nelson D, Hislop N, Gosselin G, Stashko N, Dittrich D (2017) Escherichia coli O157:H7 infections associated with contaminated pork products—Alberta, Canada, July–October 2014. MMWR Morb Mortal Wkly Rep 65(52):1477–1481PubMedGoogle Scholar
  52. Hopkins WJ, Elkahwaji J, Beierle LM, Leverson GE, Uehling DT (2007) Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol 177(4):1349–1353 (quiz 1591)PubMedGoogle Scholar
  53. Huttner A, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frölich R, Dreyer AM, Martin P, Davies T, Fae K, van den Nieuwenhof I, Thoelen S, de Vallière S, Kuhn A, Bernasconi E, Viereck V, Kavvadias T, Kling K, Ryu G, Hülder T, Gröger S, Scheiner D, Alaimo C, Harbarth S, Poolman J, Fonck VG (2017) Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis 17(5):528–537PubMedGoogle Scholar
  54. Iguchi A, Thomson NR, Ogura Y, Saunders D, Ooka T, Henderson IR, Harris D, Asadulghani M, Kurokawa K, Dean P, Kenny B, Quail MA, Thurston S, Dougan G, Hayashi T, Parkhill J, Frankel G (2009) Complete genome sequence and comparative genome analysis of enteropathogenic Escherichia coli O127:H6 strain E2348/69. J Bacteriol 191(1):347–354PubMedGoogle Scholar
  55. Johnson JR, Miller S, Johnston B, Clabots C, Debroy C (2009) Sharing of Escherichia coli sequence type ST131 and other multidrug-resistant and urovirulent E. coli strains among dogs and cats within a household. J Clin Microbiol 47(11):3721–3725PubMedPubMedCentralGoogle Scholar
  56. Kaczmarek A, Budzynska A, Gospodarek E (2014) Detection of K1 antigen of Escherichia coli rods isolated from pregnant women and neonates. Folia Microbiol 59(5):419–422Google Scholar
  57. Kaijser B, Larsson P, Nimmich W, Soderstrom T (1983a) Antibodies to Escherichia coli K and O antigens in protection against acute pyelonephritis. Prog Allergy 33:275–288PubMedGoogle Scholar
  58. Kaijser B, Larsson P, Olling S, Schneerson R (1983b) Protection against acute, ascending pyelonephritis caused by Escherichia coli in rats, using isolated capsular antigen conjugated to bovine serum albumin. Infect Immun 39(1):142–146PubMedPubMedCentralGoogle Scholar
  59. Kansal R, Rasko DA, Sahl JW, Munson GP, Roy K, Luo Q, Sheikh A, Kuhne KJ, Fleckenstein JM (2013) Transcriptional modulation of enterotoxigenic Escherichia coli virulence genes in response to epithelial cell interactions. Infect Immun 81(1):259–270PubMedPubMedCentralGoogle Scholar
  60. Kaper JB, Nataro JP, Mobley HL (2004) Pathogenic Escherichia coli. Nat Rev Microbiol 2(2):123–140Google Scholar
  61. Keller R, Hilton TD, Rios H, Boedeker EC, Kaper JB (2010) Development of a live oral attaching and effacing Escherichia coli vaccine candidate using Vibrio cholerae CVD 103-HgR as antigen vector. Microb Pathog 48(1):1–8PubMedGoogle Scholar
  62. Kim KS, Kim JY, Jeong IG, Paick JS, Son H, Lim DJ, Shim HB, Park WH, Jung HC, Choo MS (2010) A prospective multi-center trial of Escherichia coli extract for the prophylactic treatment of patients with chronically recurrent cystitis. J Korean Med Sci 25(3):435–439PubMedPubMedCentralGoogle Scholar
  63. Kochiashvili D, Khuskivadze A, Kochiashvili G, Koberidze G, Kvakhajelidze V (2014) Role of the bacterial vaccine Solco-Urovac(R) in treatment and prevention of recurrent urinary tract infections of bacterial origin. Georgian Med News 231:11–16Google Scholar
  64. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omore R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I, Nhampossa T, Acacio S, Biswas K, O’Reilly CE, Mintz ED, Berkeley LY, Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM (2013) Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382(9888):209–222PubMedGoogle Scholar
  65. Kumar A, Hays M, Lim F, Foster LJ, Zhou M, Zhu G, Miesner T, Hardwidge PR (2015) Protective enterotoxigenic Escherichia coli antigens in a murine intranasal challenge model. PLoS Negl Trop Dis 9(8):e0003924PubMedPubMedCentralGoogle Scholar
  66. Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE, O. Child Health epidemiology reference group of the World Health and Unicef (2013) Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. PLoS One 8(9):e72788PubMedPubMedCentralGoogle Scholar
  67. Langermann S, Ballou WR Jr (2001) Vaccination utilizing the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections. J Infect Dis 183(Suppl 1):S84–S86PubMedGoogle Scholar
  68. Langermann S, Mollby R, Burlein JE, Palaszynski SR, Auguste CG, DeFusco A, Strouse R, Schenerman MA, Hultgren SJ, Pinkner JS, Winberg J, Guldevall L, Soderhall M, Ishikawa K, Normark S, Koenig S (2000) Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis 181(2):774–778PubMedGoogle Scholar
  69. Laupland KB, Church DL (2014) Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev 27(4):647–664PubMedPubMedCentralGoogle Scholar
  70. Leimbach A, Hacker J, Dobrindt U (2013) E. coli as an all-rounder: the thin line between commensalism and pathogenicity. Curr Top Microbiol Immunol 358:3–32PubMedGoogle Scholar
  71. Leitner DR, Lichtenegger S, Temel P, Zingl FG, Ratzberger D, Roier S, Schild-Prufert K, Feichter S, Reidl J, Schild S (2015) A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles. Front Microbiol 6:823PubMedPubMedCentralGoogle Scholar
  72. Lin R, Zhu B, Zhang Y, Bai Y, Zhi F, Long B, Li Y, Wu Y, Wu X, Fan H (2017) Intranasal immunization with novel EspA-Tir-M fusion protein induces protective immunity against enterohemorrhagic Escherichia coli O157:H7 challenge in mice. Microb Pathog 105:19–24PubMedGoogle Scholar
  73. Lipsitch M, Siber GR (2016) How can vaccines contribute to solving the antimicrobial resistance problem? MBio 7(3)Google Scholar
  74. Lloyd JC, Hornik CP, Benjamin DK, Clark RH, Routh JC, Smith PB (2016) Incidence of breakthrough urinary tract infection in hospitalized infants receiving antibiotic prophylaxis. Clin Pediatr (Phila)Google Scholar
  75. Lo Y, Zhang L, Foxman B, Zollner S (2015) Whole-genome sequencing of uropathogenic Escherichia coli reveals long evolutionary history of diversity and virulence. Infect Genet Evol 34:244–250PubMedPubMedCentralGoogle Scholar
  76. Logue CM, Doetkott C, Mangiamele P, Wannemuehler YM, Johnson TJ, Tivendale KA, Li G, Sherwood JS, Nolan LK (2012) Genotypic and phenotypic traits that distinguish neonatal meningitis-associated Escherichia coli from fecal E. coli isolates of healthy human hosts. Appl Environ Microbiol 78(16):5824–5830PubMedPubMedCentralGoogle Scholar
  77. Lorenzo-Gomez MF, Padilla-Fernandez B, Garcia-Criado FJ, Miron-Canelo JA, Gil-Vicente A, Nieto-Huertos A, Silva-Abuin JM (2013) Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int Urogynecol J 24(1):127–134PubMedGoogle Scholar
  78. Luan J, Zhuang Z, Liu Y, Yun K, Chen M, Wang PG (2010) Expression of EspA in Lactococcus lactis NZ9000 and the detection of its immune effect in vivo and vitro. Immunopharmacol Immunotoxicol 32(1):133–140PubMedGoogle Scholar
  79. Luiz WB, Rodrigues JF, Crabb JH, Savarino SJ, Ferreira LC (2015) Maternal vaccination with a fimbrial tip adhesin and passive protection of neonatal mice against lethal human enterotoxigenic Escherichia coli challenge. Infect Immun 83(12):4555–4564PubMedPubMedCentralGoogle Scholar
  80. Lundgren A, Bourgeois L, Carlin N, Clements J, Gustafsson B, Hartford M, Holmgren J, Petzold M, Walker R, Svennerholm AM (2014) Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study. Vaccine 32(52):7077–7084PubMedGoogle Scholar
  81. Luo Q, Kumar P, Vickers TJ, Sheikh A, Lewis WG, Rasko DA, Sistrunk J, Fleckenstein JM (2014) Enterotoxigenic Escherichia coli secretes a highly conserved mucin-degrading metalloprotease to effectively engage intestinal epithelial cells. Infect Immun 82(2):509–521PubMedPubMedCentralGoogle Scholar
  82. Magasi P, Panovics J, Illes A, Nagy M (1994) Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. Eur Urol 26(2):137–140PubMedGoogle Scholar
  83. Mathers AJ, Peirano G, Pitout JD (2015) Escherichia coli ST131: the quintessential example of an international multiresistant high-risk clone. Adv Appl Microbiol 90:109–154PubMedGoogle Scholar
  84. Matthews L, Reeve R, Gally DL, Low JC, Woolhouse ME, McAteer SP, Locking ME, Chase-Topping ME, Haydon DT, Allison LJ, Hanson MF, Gunn GJ, Reid SW (2013) Predicting the public health benefit of vaccinating cattle against Escherichia coli O157. Proc Natl Acad Sci U S A 110(40):16265–16270PubMedPubMedCentralGoogle Scholar
  85. McNeilly TN, Mitchell MC, Corbishley A, Nath M, Simmonds H, McAteer SP, Mahajan A, Low JC, Smith DG, Huntley JF, Gally DL (2015) Optimizing the protection of cattle against Escherichia coli O157:H7 colonization through immunization with different combinations of H7 Flagellin, Tir, Intimin-531 or EspA. PLoS ONE 10(5):e0128391PubMedPubMedCentralGoogle Scholar
  86. Mellata M, Mitchell NM, Schodel F, Curtiss R 3rd, Pier GB (2016) Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis. Vaccine 34(5):656–662PubMedGoogle Scholar
  87. Micenkova L, Bosak J, Vrba M, Sevcikova A, Smajs D (2016) Human extraintestinal pathogenic Escherichia coli strains differ in prevalence of virulence factors, phylogroups, and bacteriocin determinants. BMC Microbiol 16:218PubMedPubMedCentralGoogle Scholar
  88. Mobley HL, Alteri CJ (2015) Development of a vaccine against Escherichia coli urinary tract infections. Pathogens 5(1)PubMedCentralGoogle Scholar
  89. Mohawk KL, Melton-Celsa AR, Robinson CM, O’Brien AD (2010) Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7. Vaccine 28(30):4777–4785PubMedPubMedCentralGoogle Scholar
  90. Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B, Pastorello I, Corea VA, Torricelli G, Cartocci E, Savino S, Scarselli M, Dobrindt U, Hacker J, Tettelin H, Tallon LJ, Sullivan S, Wieler LH, Ewers C, Pickard D, Dougan G, Fontana MR, Rappuoli R, Pizza M, Serino L (2010) Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A 107(20):9072–9077PubMedPubMedCentralGoogle Scholar
  91. Moriel DG, Rosini R, Seib KL, Serino L, Pizza M, Rappuoli R (2012) Escherichia coli: great diversity around a common core. MBio 3(3)Google Scholar
  92. Nesta B, Spraggon G, Alteri C, Moriel DG, Rosini R, Veggi D, Smith S, Bertoldi I, Pastorello I, Ferlenghi I, Fontana MR, Frankel G, Mobley HL, Rappuoli R, Pizza M, Serino L, Soriani M (2012) FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio 3(2)Google Scholar
  93. Nesta B, Valeri M, Spagnuolo A, Rosini R, Mora M, Donato P, Alteri CJ, Del Vecchio M, Buccato S, Pezzicoli A, Bertoldi I, Buzzigoli L, Tuscano G, Falduto M, Rippa V, Ashhab Y, Bensi G, Fontana MR, Seib KL, Mobley HL, Pizza M, Soriani M, Serino L (2014) SslE elicits functional antibodies that impair in vitro mucinase activity and in vivo colonization by both intestinal and extraintestinal Escherichia coli strains. PLoS Pathog 10(5):e1004124PubMedPubMedCentralGoogle Scholar
  94. Nguyen QN, Himes JE, Martinez DR, Permar SR (2016) The impact of the Gut Microbiota on humoral immunity to pathogens and vaccination in early infancy. PLoS Pathog 12(12):e1005997PubMedPubMedCentralGoogle Scholar
  95. Nicolas-Chanoine MH, Bertrand X, Madec JY (2014) Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 27(3):543–574PubMedPubMedCentralGoogle Scholar
  96. Nordstrom L, Liu CM, Price LB (2013) Foodborne urinary tract infections: a new paradigm for antimicrobial-resistant foodborne illness. Front Microbiol 4:29PubMedPubMedCentralGoogle Scholar
  97. Norman JM, Handley SA, Virgin HW (2014) Kingdom-agnostic metagenomics and the importance of complete characterization of enteric microbial communities. Gastroenterology 146(6):1459–1469PubMedPubMedCentralGoogle Scholar
  98. Norton EB, Lawson LB, Freytag LC, Clements JD (2011) Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol 18(4):546–551PubMedPubMedCentralGoogle Scholar
  99. Norton EB, Lawson LB, Mahdi Z, Freytag LC, Clements JD (2012) The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect Immun 80(7):2426–2435PubMedPubMedCentralGoogle Scholar
  100. Norton EB, Branco LM, Clements JD (2015) Evaluating the A-subunit of the Heat-Labile Toxin (LT) as an immunogen and a protective antigen against enterotoxigenic Escherichia coli (ETEC). PLoS ONE 10(8):e0136302PubMedPubMedCentralGoogle Scholar
  101. O’Hanley P, Lalonde G, Ji G (1991) Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis. Infect Immun 59(3):1153–1161PubMedPubMedCentralGoogle Scholar
  102. Ohland CL, Macnaughton WK (2010) Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298(6):G807–G819PubMedGoogle Scholar
  103. Oliveira AF, Cardoso SA, Almeida FB, de Oliveira LL, Pitondo-Silva A, Soares SG, Hanna ES (2012) Oral immunization with attenuated Salmonella vaccine expressing Escherichia coli O157:H7 intimin gamma triggers both systemic and mucosal humoral immunity in mice. Microbiol Immunol 56(8):513–522PubMedGoogle Scholar
  104. Orskov F, Orskov I (1992) Escherichia coli serotyping and disease in man and animals. Can J Microbiol 38(7):699–704PubMedGoogle Scholar
  105. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL, Luzzi E, Manetti R, Marchetti E, Mora M, Nuti S, Ratti G, Santini L, Savino S, Scarselli M, Storni E, Zuo P, Broeker M, Hundt E, Knapp B, Blair E, Mason T, Tettelin H, Hood DW, Jeffries AC, Saunders NJ, Granoff DM, Venter JC, Moxon ER, Grandi G, Rappuoli R (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459):1816–1820PubMedGoogle Scholar
  106. Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, Mills KH, Rappuoli R, Del Giudice G (2001) Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19(17–19):2534–2541PubMedGoogle Scholar
  107. Poolman JT, Wacker M (2016) Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field. J Infect Dis 213(1):6–13PubMedGoogle Scholar
  108. Punina NV, Makridakis NM, Remnev MA, Topunov AF (2015) Whole-genome sequencing targets drug-resistant bacterial infections. Hum Genomics 9:19PubMedPubMedCentralGoogle Scholar
  109. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Meta HITC, Bork P, Ehrlich SD, Wang J (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464(7285):59–65PubMedPubMedCentralGoogle Scholar
  110. Rabinovitz BC, Gerhardt E, Tironi Farinati C, Abdala A, Galarza R, Vilte DA, Ibarra C, Cataldi A, Mercado EC (2012) Vaccination of pregnant cows with EspA, EspB, gamma-intimin, and Shiga toxin 2 proteins from Escherichia coli O157:H7 induces high levels of specific colostral antibodies that are transferred to newborn calves. J Dairy Sci 95(6):3318–3326PubMedGoogle Scholar
  111. Ranallo RT, Fonseka CP, Cassels F, Srinivasan J, Venkatesan MM (2005) Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infect Immun 73(1):258–267PubMedPubMedCentralGoogle Scholar
  112. Rappuoli R (2001a) Conjugates and reverse vaccinology to eliminate bacterial meningitis. Vaccine 19(17–19):2319–2322PubMedGoogle Scholar
  113. Rappuoli R (2001b) Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19(17–19):2688–2691PubMedGoogle Scholar
  114. Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F, Paxinos EE, Sebra R, Chin CS, Iliopoulos D, Klammer A, Peluso P, Lee L, Kislyuk AO, Bullard J, Kasarskis A, Wang S, Eid J, Rank D, Redman JC, Steyert SR, Frimodt-Moller J, Struve C, Petersen AM, Krogfelt KA, Nataro JP, Schadt EE, Waldor MK (2011) Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 365(8):709–717PubMedPubMedCentralGoogle Scholar
  115. Riddle MS, Savarino SJ (2014) Moving beyond a heat-labile enterotoxin-based vaccine against enterotoxigenic Escherichia coli. Lancet Infect Dis 14(3):174–175PubMedGoogle Scholar
  116. Robins-Browne RM, Holt KE, Ingle DJ, Hocking DM, Yang J, Tauschek M (2016) Are Escherichia coli pathotypes still relevant in the era of whole-genome sequencing? Front Cell Infect Microbiol 6:141PubMedPubMedCentralGoogle Scholar
  117. Rojas RL, Gomes PA, Bentancor LV, Sbrogio-Almeida ME, Costa SO, Massis LM, Ferreira RC, Palermo MS, Ferreira LC (2010) Salmonella enterica serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli. Clin Vaccine Immunol 17(4):529–536PubMedPubMedCentralGoogle Scholar
  118. Roubaud Baudron C, Panhard X, Clermont O, Mentre F, Fantin B, Denamur E, Lefort A, C. Group (2014) Escherichia coli bacteraemia in adults: age-related differences in clinical and bacteriological characteristics, and outcome. Epidemiol Infect 142(12):2672–2683Google Scholar
  119. Roy K, Hamilton DJ, Fleckenstein JM (2012) Cooperative role of antibodies against heat-labile toxin and the EtpA Adhesin in preventing toxin delivery and intestinal colonization by enterotoxigenic Escherichia coli. Clin Vaccine Immunol 19(10):1603–1608PubMedPubMedCentralGoogle Scholar
  120. Roy K, Hilliard GM, Hamilton DJ, Luo J, Ostmann MM, Fleckenstein JM (2009) Enterotoxigenic Escherichia coli EtpA mediates adhesion between flagella and host cells. Nature 457(7229):594–598PubMedGoogle Scholar
  121. Ruan X, Robertson DC, Nataro JP, Clements JD, Zhang W, S.T.T.V.C. Group (2014). Characterization of heat-stable (STa) toxoids of enterotoxigenic Escherichia coli fused to double mutant heat-labile toxin peptide in inducing neutralizing anti-STa antibodies. Infect Immun 82(5):1823–1832PubMedPubMedCentralGoogle Scholar
  122. Ruan X, Sack DA, Zhang W (2015) Genetic fusions of a CFA/I/II/IV MEFA (multiepitope fusion antigen) and a toxoid fusion of heat-stable toxin (STa) and heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC) retain broad anti-CFA and antitoxin antigenicity. PLoS ONE 10(3):e0121623PubMedPubMedCentralGoogle Scholar
  123. Russo TA, Johnson JR (2006) Extraintestinal isolates of Escherichia coli: identification and prospects for vaccine development. Expert Rev Vaccines 5(1):45–54PubMedGoogle Scholar
  124. Sack DA, Shimko J, Torres O, Bourgeois AL, Francia DS, Gustafsson B, Karnell A, Nyquist I, Svennerholm AM (2007) Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 25(22):4392–4400PubMedGoogle Scholar
  125. Schmidhammer S, Ramoner R, Holtl L, Bartsch G, Thurnher M, Zelle-Rieser C (2002) An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology 60(3):521–526PubMedGoogle Scholar
  126. Sharapov UM, Wendel AM, Davis JP, Keene WE, Farrar J, Sodha S, Hyytia-Trees E, Leeper M, Gerner-Smidt P, Griffin PM, Braden C, Outbreak Investigation T (2016) Multistate Outbreak of Escherichia coli O157:H7 infections associated with consumption of fresh Spinach: United States, 2006. J Food Prot 79(12):2024–2030PubMedGoogle Scholar
  127. Sheikh A, Luo Q, Roy K, Shabaan S, Kumar P, Qadri F, Fleckenstein JM (2014) Contribution of the highly conserved EaeH surface protein to enterotoxigenic Escherichia coli pathogenesis. Infect Immun 82(9):3657–3666PubMedPubMedCentralGoogle Scholar
  128. Sincock SA, Hall ER, Woods CM, O’Dowd A, Poole ST, McVeigh AL, Nunez G, Espinoza N, Miller M, Savarino SJ (2016) Immunogenicity of a prototype enterotoxigenic Escherichia coli adhesin vaccine in mice and nonhuman primates. Vaccine 34(2):284–291PubMedGoogle Scholar
  129. Sivick KE, Mobley HL (2009) An “omics” approach to uropathogenic Escherichia coli vaccinology. Trends Microbiol 17(10):431–432PubMedPubMedCentralGoogle Scholar
  130. Srivastava A, Gowda DV, Madhunapantula V, Siddaramaiah S (2016) Development and efficacy assessment of an enteric coated porous tablet loaded with F4 fimbriae for oral vaccination of piglets against F4+ Escherichia coli infections. Curr Drug Deliv 13(1):121–130PubMedGoogle Scholar
  131. Takeyama N, Yuki Y, Tokuhara D, Oroku K, Mejima M, Kurokawa S, Kuroda M, Kodama T, Nagai S, Ueda S, Kiyono H (2015) Oral rice-based vaccine induces passive and active immunity against enterotoxigenic E. coli-mediated diarrhea in pigs. Vaccine 33(39):5204–5211PubMedGoogle Scholar
  132. Tammen H (1990) Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group. Br J Urol 65(1):6–9PubMedGoogle Scholar
  133. Taxt A, Aasland R, Sommerfelt H, Nataro J, Puntervoll P (2010) Heat-stable enterotoxin of enterotoxigenic Escherichia coli as a vaccine target. Infect Immun 78(5):1824–1831PubMedPubMedCentralGoogle Scholar
  134. Uehling DT, Hopkins WJ, Beierle LM, Kryger JV, Heisey DM (2001) Vaginal mucosal immunization for recurrent urinary tract infection: extended phase II clinical trial. J Infect Dis 183(Suppl 1):S81–S83PubMedGoogle Scholar
  135. Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE (2003) Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol 170(3):867–869PubMedGoogle Scholar
  136. Uehling DT, Wolf L (1969) Enhancement of the bladder defense mechanism by immunization. Invest Urol 6(5):520–526PubMedGoogle Scholar
  137. Valeri M, Rossi Paccani S, Kasendra M, Nesta B, Serino L, Pizza M, Soriani M (2015) Pathogenic E. coli exploits SslE mucinase activity to translocate through the mucosal barrier and get access to host cells. PLoS ONE 10(3):e0117486PubMedPubMedCentralGoogle Scholar
  138. Vigil PD, Alteri CJ, Mobley HL (2011) Identification of in vivo-induced antigens including an RTX family exoprotein required for uropathogenic Escherichia coli virulence. Infect Immun 79(6):2335–2344PubMedPubMedCentralGoogle Scholar
  139. Wagenlehner FM, Ballarini S, Pilatz A, Weidner W, Lehr L, Naber KG (2015) A randomized, double-blind, parallel-group, multicenter clinical study of Escherichia coli-lyophilized lysate for the prophylaxis of recurrent uncomplicated urinary tract infections. Urol Int 95(2):167–176PubMedGoogle Scholar
  140. Walker WA (2013) Initial intestinal colonization in the human infant and immune homeostasis. Ann Nutr Metab 63(Suppl 2):8–15PubMedGoogle Scholar
  141. Whitfield C (2006) Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem 75:39–68PubMedGoogle Scholar
  142. Wieser A, Romann E, Magistro G, Hoffmann C, Norenberg D, Weinert K, Schubert S (2010) A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice. Infect Immun 78(8):3432–3442PubMedPubMedCentralGoogle Scholar
  143. Wu HJ, Wu E (2012) The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes 3(1):4–14PubMedPubMedCentralGoogle Scholar
  144. Yang J, Baldi DL, Tauschek M, Strugnell RA, Robins-Browne RM (2007) Transcriptional regulation of the yghJ-pppA-yghG-gspCDEFGHIJKLM cluster, encoding the type II secretion pathway in enterotoxigenic Escherichia coli. J Bacteriol 189(1):142–150PubMedGoogle Scholar
  145. Zhang W, Sack DA (2015) Current Progress in developing subunit vaccines against enterotoxigenic Escherichia coli-associated diarrhea. Clin Vaccine Immunol 22(9):983–991PubMedPubMedCentralGoogle Scholar
  146. Zhang XH, He KW, Zhang SX, Lu WC, Zhao PD, Luan XT, Ye Q, Wen LB, Li B, Guo RL, Wang XM, Lv LX, Zhou JM, Yu ZY, Mao AH (2011) Subcutaneous and intranasal immunization with Stx2B-Tir-Stx1B-Zot reduces colonization and shedding of Escherichia coli O157:H7 in mice. Vaccine 29(22):3923–3929PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.GSKSienaItaly

Personalised recommendations